Christine O'Brien is the founder of Tizona Therapeutics. Tizona Therapeutics has raised $43M in total funding. Latest round: Series B.
Christine O'Brien is the Chief Executive Officer at Tizona Therapeutics, a privately held, clinical-stage company developing first-in-class cancer immunotherapies. Tizona translates scientific breakthroughs into therapeutics that stimulate the immune system and counter immune suppression. In 2020, Tizona entered into a transformative alliance with Gilead Sciences, involving Gilead purchasing a 49.9 percent equity interest and an exclusive option to acquire the remainder. O'Brien joined Tizona in 2015, previously serving as Chief Operating Officer, and has played a significant role in advancing two first-in-class immunotherapies into the clinic.
Full founder directory · Investor directory · Company funding database · Fundraising library